Literature DB >> 33626235

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.

Jun Ho Yi1, Seok Jin Kim2, Dok Hyun Yoon3, Cheolwon Suh3, Myung Hee Chang4, Deok Hwan Yang5, Jae-Cheol Jo6, Shin Young Hyun7, Hyeon-Seok Eom8, Jeong-Ok Lee9, Ji Hyun Kwon10, Sang Hoon Han11, Seung-Shin Lee12, Jae-Yong Kwak13, Se Hyung Kim14, Dae Sik Kim15, Ji Hyun Lee16, Sung Yong Oh16, Hun Mo Ryoo17, Hyo Jung Kim18, Won Seog Kim2.   

Abstract

Entities:  

Year:  2021        PMID： 33626235     DOI： 10.1002/cac2.12150

Source DB:  PubMed          Journal:  Cancer Commun (Lond)        ISSN： 2523-3548


× No keyword cloud information.
  1 in total

1.  IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.

Authors:  Juan-Manuel Sancho; Ana Marín-Niebla; Silvia Fernández; Francisco-Javier Capote; Carolina Cañigral; Carlos Grande; Eva Donato; Izaskun Zeberio; Jose-Manuel Puerta; Alfredo Rivas; Elena Pérez-Ceballos; Ana Vale; Alejandro Martín García-Sancho; Antonio Salar; Eva González-Barca; Anabel Teruel; Carmen Pastoriza; Diego Conde-Royo; Joaquín Sánchez-García; Cristina Barrenetxea; Reyes Arranz; José-Ángel Hernández-Rivas; María-José Ramírez; Aroa Jiménez; Eva Rubio-Azpeitia
Journal:  Int J Hematol       Date:  2022-05-13       Impact factor: 2.319
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.